Navigation Links
Cadence Pharmaceuticals Completes $86.6 Million Private Placement of Common Stock
Date:2/19/2009

t Cadence Pharmaceuticals, Inc.

Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. The company currently has two Phase III product candidates in development, Acetavance(TM) (intravenous acetaminophen) for the treatment of acute pain and fever, and Omigard(TM) (omiganan pentahydrochloride 1% topical gel) for the prevention of catheter-related infections. For more information about Cadence's pipeline, visit www.cadencepharm.com.

Forward-Looking Statements

Statements included in this press release that are not a description of historical facts are forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Cadence that any of its plans will be achieved. Actual results may also differ from those projected in forward-looking statements due to risks and uncertainties that exist in the Company's operations and business environments, including the possible need to raise additional capital and the possibility that Cadence's share price may decline after the transaction is closed. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Cadence undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.

Cadence(TM), Acetavance(TM) and Omigard(TM) are trademarks of Cadence Pharmaceuticals, Inc.

    Contacts:   William R. LaRue
      
'/>"/>
SOURCE  Cadence Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 

Related medicine news :

1. Cadence Pharmaceuticals Chief Medical Officer James Breitmeyer to Present at JMP Securities Healthcare Focus Conference
2. Cadence Pharmaceuticals Announces Topline Results of Two Phase III Clinical Trials of Acetavance(TM)
3. Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results and Provides Corporate and Clinical Program Overview
4. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter Financial Results and Provide a Clinical Program Update on May 6, 2008
5. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference on June 11, 2008 in New York
6. Cadence Pharmaceuticals Announces Positive Topline Results of Phase III Clinical Trial of Acetavance in Laparoscopic Surgery
7. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the BIO CEO and Investor Conference in New York City
8. Cadence Pharmaceuticals to Raise $86.6 Million in a Private Placement of Common Stock
9. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
10. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
11. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... This week is National EMS Week, which ... provide the best emergency care and to improve health ... also to educate the public that all can play ... the first link, and a very important one. According ... a cardiac arrest can triple a victim’s chance of ...
(Date:5/24/2013)... hospitalized for heart failure appear to have better odds ... the morning, a new study finds. Death rates ... patients admitted in January, on Fridays and overnight, according ... findings Saturday in Portugal at the annual meeting of ... Cardiology. "The fact that patients admitted right ...
(Date:5/24/2013)... Florida (PRWEB) May 24, 2013 KC and ... the Title Sponsors for FreeRide836. Their oldest sons, Kyle and ... and Tracey Russell family and several professional kiteboarders. , KC ... amazing project. "This has miraculously come together such that virtually ... able to participate." , 20 kite boarders will meet at ...
(Date:5/24/2013)... May 24 (HealthDay News) -- New research suggests ... among people with insomnia. Every additional hour ... 72 percent drop in the likelihood of moderate ... from the University of Pennsylvania. "We ... between sleep duration and suicide risk," study author, ...
(Date:5/24/2013)... (PRWEB) May 24, 2013 Gift ... Cards, major competitors in sustainable card material, are ... using forest materials as a sustainable gift card ... to identify industry challenges and increase education and ... programs to support the reduction of carbon footprint ...
Breaking Medicine News(10 mins):Health News:Acadian Medics Reunite with Miracle Baby 2Health News:Monday Best Time for Hospitalization With Heart Failure, Study Says 2Health News:FreeRide836 Sponsor Living Fuel, The Leader in Superfood Nutrition, Announces Kiteboard Launch For This Sunday To Raise Money For Orphans In Africa 2Health News:FreeRide836 Sponsor Living Fuel, The Leader in Superfood Nutrition, Announces Kiteboard Launch For This Sunday To Raise Money For Orphans In Africa 3Health News:Sleep Duration Linked to Suicidal Thoughts in People With Insomnia 2Health News:Making Gift Cards Greener- Competitors Combine Efforts to Educate and Empower Merchants 2Health News:Making Gift Cards Greener- Competitors Combine Efforts to Educate and Empower Merchants 3
... Agitating medicos today sought divine intervention in their anti-quota ... leaders, who were pushing for OBC reservation// in elite ... Post Graduate Institute for Medical Education and Research and ... Gurudwara Nada Sahib to pray to God to give ...
... suffer from rejection of the organ. Hence according ... anti-rejection drug, cyclosporine significantly reduces// rejection and results ... presented at the American Thoracic Society International Conference. ... previously found that inhaled cyclosporine improved survival and ...
... If you thought that, people who actually face tough times ... in life, a startling study has revealed exactly// the contrary. ... such people are the ones who are vulnerable to deception ... ,A six-month study in the University's School of Psychology found ...
... study conducted by researchers at the Washington University and the ... was found// that regular exercise keeps Alzheimer’s at bay. It ... the disease but now it is been disproved by the ... that balance problems and a weak handshake are early signs ...
... has highlighted the beneficial effects of consuming flavanol-rich cocoa ... the Journal of Nutrition//. ,Researchers found that ... appearance of women's skin – increasing hydration, decreasing skin ... defense against UV damage. The German scientists attributed the ...
... same day Prince Charles urges the World Health Assembly ... complementary medicines alongside scientifically// proven treatments, some of UK’s ... into the NHS. ,Thirteen senior doctors who ... medicine have written to every hospital and primary care ...
Cached Medicine News:Health News:Inhaled Cyclosporine Results In Rejection Free Survival among Lung Transplant Patients 2Health News:Take it if you can - Tough Times in Life Churn out Greenhorns 2Health News:Take it if you can - Tough Times in Life Churn out Greenhorns 3Health News:Cocoa good for skin? 2Health News:Eminent Doctors In UK Wants The NHS To Abandon Alternative Medicines: 2
(Date:5/23/2013)... IRVINE, Calif. , May 23, 2013 ... breast cancer may not benefit from chemotherapy and still ... announced the launch of one of the largest sources ... The new website and interactive Facebook page provide recently ... if they can safely avoid chemotherapy. "We ...
(Date:5/23/2013)... , May 23, 2013  Every day, their baby ... air to his lungs. April and Bryan Gionfriddo ... predictions weren,t true. "Quite a few doctors said ... alive," says April Gionfriddo , about her ... Anything that would work, we would take it and run ...
(Date:5/23/2013)... May 23, 2013  Spring Bank Pharmaceuticals, Inc., a ... viral infections, today announced that it has initiated dosing ... investigational, once daily, oral therapy for the treatment of ... patients and is designed to assess both the safety ... a first-in-class drug for the treatment of chronic HCV ...
Breaking Medicine Technology:Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions 2Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions 3Baby's life saved with groundbreaking 3D printed device from U-M that restored his breathing 2Baby's life saved with groundbreaking 3D printed device from U-M that restored his breathing 3Baby's life saved with groundbreaking 3D printed device from U-M that restored his breathing 4Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients 2Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients 3
... 13, 2011 Reportlinker.com announces that a new market ... UCB S.A.: PharmaVitae Profile ... This analysis examines the historical and forecast performance ... encompasses global company strategy, portfolio and pipeline analysis and ...
... 2011 Zimmer Holdings, Inc. (NYSE: ZMH ; ... the Zimmer NexGen LPS-Flex Mobile Bearing ... the United States.  The LPS-Flex Mobile Bearing knee provides a ... cruciate ligament (ACL), replicating the anatomic center of knee rotation. ...
Cached Medicine Technology:Reportlinker Adds UCB S.A.: PharmaVitae Profile 2Zimmer Introduces a Move Forward in Mobile Bearing Knee Design 2Zimmer Introduces a Move Forward in Mobile Bearing Knee Design 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: